James W Donaldson1, Tricia M McKeever2, Ian P Hall2, Richard B Hubbard2, Andrew W Fogarty2. 1. From the Divisions of Epidemiology and Public Health (J.W.D., T.M.M., R.B.H., A.W.F.) and Therapeutics and Molecular Medicine (I.P.H.), University of Nottingham, UK. james.donaldson@nottingham.ac.uk. 2. From the Divisions of Epidemiology and Public Health (J.W.D., T.M.M., R.B.H., A.W.F.) and Therapeutics and Molecular Medicine (I.P.H.), University of Nottingham, UK.
Abstract
OBJECTIVES: Studies report that the risks of significant neurologic complications (including stroke, cerebral abscess, and migraine) and hemorrhagic sequelae are high in patients with hereditary hemorrhagic telangiectasia (HHT), and that life expectancy in this cohort is reduced. However, most published cohorts derive from specialist centers, which may be susceptible to bias. METHODS: We used a population-based approach to estimate the risks of developing neurologic and hemorrhagic complications of HHT, the association of a diagnosis of HHT with common cardiovascular and malignant comorbidities, and also long-term survival of those with the disease. RESULTS: From a UK primary care database of 3.5 million patients (The Health Improvement Network), we identified 675 cases with a diagnosis of HHT and compared them with 6,696 controls matched by age, sex, and primary care practice. Risks of stroke (odds ratio [OR] 1.8, 95% confidence interval [CI] 1.2-2.6), cerebral abscess (OR 30.0, CI 3.1-288), and migraine (OR 1.7, CI 1.3-2.2) were elevated over controls. Bleeding complications including epistaxis (OR 11.6, CI 9.1-14.7) and gastrointestinal hemorrhage (OR 6.1, CI 2.8-13.4) were more common in cases with HHT. Survival of cases with HHT was poorer than controls with a hazard ratio for death of 2.0 (CI 1.6-2.6) and a median age at death 3 years younger. CONCLUSIONS: Patients with HHT are at substantially increased risk of serious neurologic and hemorrhagic complications of the disease. Because a diagnosis of HHT is associated with a significantly poorer survival compared with those who have no disease, evaluation of new strategies to improve clinical management is required.
OBJECTIVES: Studies report that the risks of significant neurologic complications (including stroke, cerebral abscess, and migraine) and hemorrhagic sequelae are high in patients with hereditary hemorrhagic telangiectasia (HHT), and that life expectancy in this cohort is reduced. However, most published cohorts derive from specialist centers, which may be susceptible to bias. METHODS: We used a population-based approach to estimate the risks of developing neurologic and hemorrhagic complications of HHT, the association of a diagnosis of HHT with common cardiovascular and malignant comorbidities, and also long-term survival of those with the disease. RESULTS: From a UK primary care database of 3.5 million patients (The Health Improvement Network), we identified 675 cases with a diagnosis of HHT and compared them with 6,696 controls matched by age, sex, and primary care practice. Risks of stroke (odds ratio [OR] 1.8, 95% confidence interval [CI] 1.2-2.6), cerebral abscess (OR 30.0, CI 3.1-288), and migraine (OR 1.7, CI 1.3-2.2) were elevated over controls. Bleeding complications including epistaxis (OR 11.6, CI 9.1-14.7) and gastrointestinal hemorrhage (OR 6.1, CI 2.8-13.4) were more common in cases with HHT. Survival of cases with HHT was poorer than controls with a hazard ratio for death of 2.0 (CI 1.6-2.6) and a median age at death 3 years younger. CONCLUSIONS:Patients with HHT are at substantially increased risk of serious neurologic and hemorrhagic complications of the disease. Because a diagnosis of HHT is associated with a significantly poorer survival compared with those who have no disease, evaluation of new strategies to improve clinical management is required.
Authors: Margaret O'Malley; Lisa LaGuardia; Matthew F Kalady; Joseph Parambil; Brandie Heald; Charis Eng; James Church; Carol A Burke Journal: Dis Colon Rectum Date: 2012-08 Impact factor: 4.585
Authors: C L Shovlin; A E Guttmacher; E Buscarini; M E Faughnan; R H Hyland; C J Westermann; A D Kjeldsen; H Plauchu Journal: Am J Med Genet Date: 2000-03-06
Authors: C L Shovlin; J E Jackson; K B Bamford; I H Jenkins; A R Benjamin; H Ramadan; E Kulinskaya Journal: Thorax Date: 2007-11-02 Impact factor: 9.139
Authors: M Neil Woodall; Melissa McGettigan; Ramon Figueroa; James R Gossage; Cargill H Alleyne Journal: J Neurosurg Date: 2013-11-15 Impact factor: 5.115
Authors: J P Mohr; Michael K Parides; Christian Stapf; Ellen Moquete; Claudia S Moy; Jessica R Overbey; Rustam Al-Shahi Salman; Eric Vicaut; William L Young; Emmanuel Houdart; Charlotte Cordonnier; Marco A Stefani; Andreas Hartmann; Rüdiger von Kummer; Alessandra Biondi; Joachim Berkefeld; Catharina J M Klijn; Kirsty Harkness; Richard Libman; Xavier Barreau; Alan J Moskowitz Journal: Lancet Date: 2013-11-20 Impact factor: 79.321
Authors: Weiyi Mu; Zachary A Cordner; Kevin Yuqi Wang; Kate Reed; Gina Robinson; Sally Mitchell; Doris Lin Journal: Genet Med Date: 2017-10-19 Impact factor: 8.822
Authors: E M de Gussem; C P Edwards; A E Hosman; C J J Westermann; R J Snijder; M E Faughnan; J J Mager Journal: Orphanet J Rare Dis Date: 2016-04-22 Impact factor: 4.123
Authors: Ricardo Alicea-Guevara; Michael Cruz Caliz; Jose Adorno; Ricardo Fernandez; Kelvin Rivera; Gustavo Gonzalez; Ricardo Alan Hernandez-Castillo; Rosangela Fernandez; Christian Castillo Latorre Journal: Oxf Med Case Reports Date: 2018-03-22
Authors: Vivek N Iyer; Waleed Brinjikji; Dinesh Apala; Bibek S Pannu; Aditya Kotecha; Michael D Leise; Patrick S Kamath; Sanjay Misra; Giuseppe Lanzino; Michael J Krowka; Christopher P Wood; Karen L Swanson Journal: Adv Hematol Date: 2018-02-11
Authors: Joseph G Parambil; James R Gossage; Keith R McCrae; Troy D Woodard; K V Narayanan Menon; Kasi L Timmerman; Douglas P Pederson; Dennis L Sprecher; Hanny Al-Samkari Journal: Angiogenesis Date: 2021-07-22 Impact factor: 9.596